Friday, July 10, 2026

Drug profile · INN

fenfluramine hydrochloride

fenfluramine hydrochloride (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — fenfluramine hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
1
Data quality
0.84

Quick answer

fenfluramine hydrochloride (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN fenfluramine hydrochloride
Brand FINTEPLA
Mechanism Serotonin 2c (5-HT2c) receptor agonist
Target 5-hydroxytryptamine receptor 1D
Route ORAL
Formulation SOLUTION

Mechanism of action

Serotonin 2c (5-HT2c) receptor agonist

Primary target: 5-hydroxytryptamine receptor 1D

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. ZX008 (Fenfluramine Hydrochloride) Phase 3 · International Peace Maternity · Dravet Syndrome

Related & competitor drugs

  1. dihydroergotamine mesylate Serotonin 1d (5-HT1d) receptor agonist

Frequently asked questions

What is fenfluramine hydrochloride?

fenfluramine hydrochloride (FINTEPLA) is a serotonin 2c (5-ht2c) receptor agonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for fenfluramine hydrochloride?

FINTEPLA is a marketed brand name for fenfluramine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of fenfluramine hydrochloride?

fenfluramine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.